Security key
98943L107
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL)
CUSIP: 98943L107
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock,$0.001 par value per share
- Shares outstanding
- 72,096,078
- Total 13F shares
- 64,418,043
- Share change
- -7,990,971
- Total reported value
- $195,184,400
- Put/Call ratio
- 50%
- Price per share
- $3.03
- Number of holders
- 141
- Value change
- -$24,736,255
- Number of buys
- 82
- Number of sells
- 53
Report period
Q4 2024
Institutions
141
Top holders
10
ZNTL full security history
Newer quarter: Q1 2025
Previous quarter: Q3 2024
Zentalis Pharmaceuticals, Inc. SEC filings
Zentalis Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98943L107
Recent filing periods:
Top shareholders of ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
4.6%
from 13D/G
|
4,612,707
|
$16,974,762 | — | 30 Sep 2024 | |
| FMR LLC |
13F
13D/G
|
Company |
0.2%
from 13D/G
|
5,075,837
|
$18,679,080 | — | 30 Sep 2024 | |
| Matrix Capital Management Company, LP |
13F
|
Company |
19%
|
13,959,973
|
$51,372,701 | — | 30 Sep 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
12%
|
8,547,896
|
$31,456,257 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
6.6%
|
4,761,173
|
$17,521,117 | — | 30 Sep 2024 | |
| Decheng Capital LLC |
13F
|
Company |
4.3%
|
3,108,095
|
$11,437,789 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.8%
|
2,717,521
|
$10,000,477 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
2.2%
|
1,611,567
|
$5,930,567 | — | 30 Sep 2024 | |
| Verition Fund Management LLC |
13F
|
Company |
2.1%
|
1,504,320
|
$5,535,898 | — | 30 Sep 2024 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
2.1%
|
1,498,030
|
$5,512,751 | — | 30 Sep 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
2%
|
1,465,801
|
$5,394,148 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
1,292,100
|
$4,756,035 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.7%
|
1,246,613
|
$4,587,536 | — | 30 Sep 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.6%
|
1,149,400
|
$4,229,792 | — | 30 Sep 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.6%
|
1,128,577
|
$4,153,163 | — | 30 Sep 2024 | |
| Woodline Partners LP |
13F
|
Company |
1.5%
|
1,055,282
|
$3,883,438 | — | 30 Sep 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.4%
|
1,036,911
|
$3,817,000 | — | 30 Sep 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
1.3%
|
967,000
|
$3,558,560 | — | 30 Sep 2024 | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD |
13F
|
Company |
1.3%
|
961,486
|
$3,538,269 | — | 30 Sep 2024 | |
| Almitas Capital LLC |
13F
|
Company |
1.3%
|
960,928
|
$3,536,215 | — | 30 Sep 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.3%
|
908,601
|
$3,343,652 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.2%
|
886,086
|
$3,260,796 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.1%
|
775,536
|
$2,853,972 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.88%
|
634,064
|
$2,333,355 | — | 30 Sep 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.84%
|
608,585
|
$2,240,000 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.77%
|
556,944
|
$2,049,554 | — | 30 Sep 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.7%
|
505,644
|
$1,860,829 | — | 30 Sep 2024 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.68%
|
490,000
|
$1,803,200 | — | 30 Sep 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.68%
|
489,199
|
$1,800,252 | — | 30 Sep 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.67%
|
483,338
|
$1,778,684 | — | 30 Sep 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.66%
|
474,345
|
$1,745,590 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.66%
|
474,225
|
$1,745,148 | — | 30 Sep 2024 | |
| Boxer Capital, LLC |
13F
|
Company |
0.62%
|
450,000
|
$1,656,000 | — | 30 Sep 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.56%
|
406,210
|
$1,494,853 | — | 30 Sep 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.37%
|
263,216
|
$967,000 | — | 30 Sep 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.32%
|
229,138
|
$843,228 | — | 30 Sep 2024 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.27%
|
195,482
|
$719,375 | — | 30 Sep 2024 | |
| XTX Topco Ltd |
13F
|
Company |
0.27%
|
194,062
|
$714,148 | — | 30 Sep 2024 | |
| Mayo Clinic |
13F
|
Company |
0.24%
|
175,000
|
$644,000 | — | 30 Sep 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.24%
|
173,310
|
$637,781 | — | 30 Sep 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.22%
|
161,193
|
$593,190 | — | 30 Sep 2024 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.18%
|
128,124
|
$471,496 | — | 30 Sep 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.17%
|
121,095
|
$445,630 | — | 30 Sep 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.16%
|
115,105
|
$423,586 | — | 30 Sep 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.15%
|
109,538
|
$403,100 | — | 30 Sep 2024 | |
| PDT Partners, LLC |
13F
|
Company |
0.15%
|
107,159
|
$394,345 | — | 30 Sep 2024 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.15%
|
106,080
|
$397,800 | — | 30 Sep 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.12%
|
89,012
|
$327,564 | — | 30 Sep 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.12%
|
86,713
|
$319,094 | — | 30 Sep 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.11%
|
78,927
|
$290,000 | — | 30 Sep 2024 |
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) as of Q4 2024
As of 31 Dec 2024,
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) was held by
141 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,418,043 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, EVENTIDE ASSET MANAGEMENT, LLC, BlackRock, Inc., VANGUARD GROUP INC, CITADEL ADVISORS LLC, Decheng Capital LLC, Opaleye Management Inc., MORGAN STANLEY, Almitas Capital LLC, and PRIMECAP MANAGEMENT CO/CA/.
This page lists
141
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
133
Q4 2024 holders
141
Holder diff
8
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.